ARQT
NASDAQ · Biotechnology
Arcutis Biotherapeutics Inc
$21.17
+0.51 (+2.47%)
Financial Highlights (FY 2026)
Revenue
360.79M
Net Income
-15,489,433
Gross Margin
90.2%
Profit Margin
-4.3%
Rev Growth
+367.1%
D/E Ratio
0.58
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 90.2% | 45.1% | 45.1% | 45.1% |
| Operating Margin | -3.2% | 26.9% | 23.8% | 26.0% |
| Profit Margin | -4.3% | 19.0% | 16.6% | 16.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 360.79M | 947.52M | 972.47M | 976.02M |
| Gross Profit | 325.57M | 427.36M | 438.62M | 440.22M |
| Operating Income | -11,725,525 | 254.52M | 231.24M | 253.28M |
| Net Income | -15,489,433 | 179.95M | 161.28M | 155.67M |
| Gross Margin | 90.2% | 45.1% | 45.1% | 45.1% |
| Operating Margin | -3.2% | 26.9% | 23.8% | 26.0% |
| Profit Margin | -4.3% | 19.0% | 16.6% | 16.0% |
| Rev Growth | +367.1% | -4.3% | +9.4% | +5.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 471.68M | 895.84M | 846.83M | 916.46M |
| Total Equity | 820.32M | 1.15B | 1.06B | 1.22B |
| D/E Ratio | 0.58 | 0.78 | 0.80 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -11,302,769 | 271.10M | 315.26M | 309.11M |
| Free Cash Flow | — | 104.36M | 84.89M | 130.66M |